Zhejiang Doer Biologics Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING1
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| DR10624 Injection NCT07024212 |
P2 | Active, not recruiting | MASLD | 110 | 2026-06-18 |
| DR30206 NCT07056777 |
P1/2 | Recruiting | Gastrointestinal Cancer | 186 | 2027-04-30 (+12 mo) |
| DR10624 Injection NCT07848880 |
P2 | Not yet recruiting | Hypertriglyceridemia | 315 | 2028-04 |
| DR10624 Injection NCT07693777 |
P3 | Not yet recruiting | Severe Hypertriglyceridemia (sHTG); Hypertriglyceridemia | 480 | 2029-02-14 |
| DR10624 Subcutaneous Injection NCT07680829 |
P3 | Not yet recruiting | Severe Hypertriglyceridemia | 378 | 2030-06 |